Properties		Conclusion (a)
CMR	Carcinogenicity (C)	Flutolanil is considered to meet the criteria for classification as category 2 carcinogen (as agreed by the peer review in the absence of harmonised classification in ECHA) according to point 3.6.2 of Annex II of Regulation (EC) No 1107/2009.
	Mutagenicity (M)	Flutolanil is not considered to be a mutagen according to point 3.6.2 of Annex II of Regulation (EC) No 1107/2009.
	Toxic for Reproduction (R)	Flutolanil is considered to meet the criteria for classification as category 2 reproductive toxicant (as agreed by the peer review in the absence of harmonised classification in ECHA) according to point 3.6.4 of Annex II of Regulation (EC) No1107/2009.
Endocrine‐disrupting properties		Flutolanil is not considered to meet the criteria for endocrine disruption for human health and non‐target organisms according to points 3.6.5 and 3.8.2 of Annex II of Regulation No 1107/2009, as amended by Commission Regulation (EU) 2018/605.
POP	Persistence	Flutolanil is not considered to be a persistent organic pollutant (POP) according to point 3.7.1 of Annex II of Regulation (EC) 1107/2009.
	Bioaccumulation
	Long‐range transport
PBT	Persistence	Flutolanil is not considered to be a persistent, bioaccumulative and toxic (PBT) substance according to point 3.7.2 of Annex II of Regulation (EC) 1107/2009.
	Bioaccumulation
	Toxicity
vPvB	Persistence	Flutolanil is not considered to be a very persistent, very bioaccumulative substance according to point 3.7.3 of Annex II of Regulation (EC) 1107/2009.
	Bioaccumulation

^(a): Origin of data to be included where applicable (e.g. EFSA, ECHA RAC, Regulation).